<p>中國杭州，2025 年 12 月 24 日（GLOBE NEWSWIRE）-- WORK Medical Technology Group LTD（納斯達克股票代碼：WOK）（“WORK Medical” 或 “公司”），通過其子公司 Work（杭州）醫療器械有限公司及其在中國的子公司，今天宣佈將按 1 比 100 的比例進行普通股的反向拆分（“反向拆分”）。公司的 A 類普通股將在 2025 年 12 月 29 日市場開盤時開始以拆分後的基礎進行交易。公司的 A 類普通股將繼續在納斯達克資本市場以 “WOK” 符號交易，新的 CUSIP 號碼為 G9767H125。</p>
<p>反向拆分已獲得公司股東和公司董事會的批准，主要是為了保持符合納斯達克市場規則 5550(a)(2) 的要求，該規則涉及公司 A 類普通股的最低出價價格的維持。</p>
<p>任何因反向拆分而產生的零碎股份將被向上舍入至下一個整數，且不會發行零碎股份。反向拆分對所有股東均有統一影響，不會改變任何股東在公司已發行普通股中的百分比權益，除非因零碎股份的舍入而產生的調整。</p>
<p>在反向拆分生效後，截至生效日期，公司已發行和流通的每一百股 A 類普通股將自動合併為一股 A 類普通股，而截至生效日期，公司已發行和流通的每一百股 B 類普通股將自動合併為一股 B 類普通股。</p>
<p><strong>關於 WORK Medical Technology Group LTD</strong></p>
<p>WORK Medical Technology Group LTD 通過其子公司 Work（杭州）醫療器械有限公司及其在中國的子公司，是一家醫療器械供應商，開發和製造 I 類和 II 類醫療器械，並通過在中國的運營子公司銷售 I 類和 II 類一次性醫療器械。公司擁有多樣化的產品組合，包括 21 種產品，涵蓋定製和多功能口罩及其他醫療耗材。所有產品已在中國 34 個省級行政區域銷售，其中 15 種產品已在全球 30 多個國家銷售。公司獲得了多項與質量相關的製造認證，並已向美國食品藥品監督管理局註冊了 17 種產品，允許其產品進入美國市場。有關更多信息，請訪問公司網站：https://www.workmedtech.com/corporate。</p>
<p><strong><em>前瞻性聲明</em></strong></p>
<p><em>本新聞稿包含前瞻性聲明，包括根據 1995 年《私人證券訴訟改革法》安全港條款作出的聲明。這些聲明可能通過諸如 “旨在”、“預期”、“相信”、“可能”、“估計”、“期望”、“預測”、“目標”、“打算”、“可能”、“計劃”、“可能的”、“潛在的”、“尋求”、“將會” 等詞語或類似表達來識別，旨在識別前瞻性聲明。本新聞稿中任何不是歷史事實的聲明可能被視為前瞻性聲明。本新聞稿中的任何前瞻性聲明僅基於公司截至本聲明日期的當前預期、估計和預測，並受到可能導致實際結果與這些前瞻性聲明中所列或暗示的結果顯著不同的多種風險和不確定性的影響。儘管公司相信這些前瞻性聲明中表達的預期是合理的，但無法保證這些預期會被證明是正確的，公司提醒投資者，實際結果可能與預期結果顯著不同，並鼓勵投資者審查可能影響其未來結果的其他因素，這些因素在公司提交給美國證券交易委員會的 20-F 表格年報和其他文件中列出。公司明確聲明，除法律要求外，沒有義務更新任何前瞻性聲明。</em></p>
<p><strong>如需更多信息，請聯繫：</strong></p>
<p><strong>WORK Medical Technology Group LTD</strong></p>
<p>投資者關係部</p>
<p>電子郵件：ir@workmedtech.com</p>
<p><strong>Ascent Investor Relations LLC</strong></p>
<p>Tina Xiao</p>
<p>電話：+1-646-932-7242</p>
<p>電子郵件：investors@ascent-ir.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qUTROeU0zTXpNME5EazRJelV3TURFeU56UXhNUT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qUTROeU0zTXpNME5EazRJelV3TURFeU56UXhNUT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MzMwMTJhOTMtZjc1Zi00NTM1LTkyM2ItMWFhNDJjZWYwZGI5LTUwMDEyNzQxMS0yMDI1LTEyLTI0LWVu/tiny/WORK-Medical-Technology-Group-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MzMwMTJhOTMtZjc1Zi00NTM1LTkyM2ItMWFhNDJjZWYwZGI5LTUwMDEyNzQxMS0yMDI1LTEyLTI0LWVu/tiny/WORK-Medical-Technology-Group-.png"/></p>

<p>WORK Medical Technology Group LTD 宣佈將於 2025 年 12 月 29 日實施 1 股換 100 股的反向股票拆分。此舉旨在保持符合納斯達克的最低報價規則。拆分後，A 類股票將以 “WOK” 為交易代碼，並獲得新的 CUSIP 號碼。零碎股份將被向上取整。該拆分對所有股東均勻適用，不會改變他們的持股比例。WORK Medical 在中國及國際市場提供醫療設備</p>

<p>Hangzhou, China, Dec. 24, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that it will effect a reverse stock split of its ordinary shares on a 1-for-100 basis (the “Reverse Stock Split”). The Company’s Class A ordinary shares will begin trading on a post-split basis when the market opens on December 29, 2025. The Company’s Class A ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol “WOK,” with a new CUSIP number G9767H125.</p>
<div class="lb-trans"><p>中國杭州，2025 年 12 月 24 日（GLOBE NEWSWIRE）-- WORK Medical Technology Group LTD（納斯達克股票代碼：WOK）（“WORK Medical” 或 “公司”），通過其子公司 Work（杭州）醫療器械有限公司及其在中國的子公司，今天宣佈將按 1 比 100 的比例進行普通股的反向拆分（“反向拆分”）。公司的 A 類普通股將在 2025 年 12 月 29 日市場開盤時開始以拆分後的基礎進行交易。公司的 A 類普通股將繼續在納斯達克資本市場以 “WOK” 符號交易，新的 CUSIP 號碼為 G9767H125。</p>
</div><p>The Reverse Stock Split has been approved by the Company’s shareholders and the Company’s board of directors, and is being effectuated primarily to maintain compliance with Nasdaq Marketplace Rule 5550(a)(2) relating to the maintenance of the minimum bid price per share of the Company’s Class A ordinary shares.</p>
<div class="lb-trans"><p>反向拆分已獲得公司股東和公司董事會的批准，主要是為了保持符合納斯達克市場規則 5550(a)(2) 的要求，該規則涉及公司 A 類普通股的最低出價價格的維持。</p>
</div><p>Any fractional shares that would have otherwise resulted from the Reverse Stock Split will be rounded up to the next whole number and no fractional shares will be issued. The Reverse Stock Split affects all shareholders uniformly and will not alter any shareholder’s percentage interest in the Company’s outstanding ordinary shares, except for adjustments that may result from the rounding up of fractional shares.</p>
<div class="lb-trans"><p>任何因反向拆分而產生的零碎股份將被向上舍入至下一個整數，且不會發行零碎股份。反向拆分對所有股東均有統一影響，不會改變任何股東在公司已發行普通股中的百分比權益，除非因零碎股份的舍入而產生的調整。</p>
</div><p>Upon the effectiveness of the Reverse Stock Split, every one hundred shares of the Company’s issued and outstanding Class A ordinary shares as of the effective date will automatically be combined into one Class A ordinary share, and every one hundred shares of the Company’s issued and outstanding Class B ordinary shares as of the effective date will automatically be combined into one Class B ordinary share.</p>
<div class="lb-trans"><p>在反向拆分生效後，截至生效日期，公司已發行和流通的每一百股 A 類普通股將自動合併為一股 A 類普通股，而截至生效日期，公司已發行和流通的每一百股 B 類普通股將自動合併為一股 B 類普通股。</p>
</div><p><strong>About WORK Medical Technology Group LTD</strong></p>
<div class="lb-trans"><p><strong>關於 WORK Medical Technology Group LTD</strong></p>
</div><p>WORK Medical Technology Group LTD, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, is a supplier of medical devices that develops and manufactures Class I and II medical devices and sells Class I and II disposable medical devices through operating subsidiaries in China. The Company has a diverse product portfolio comprising 21 products, including customized and multifunctional masks and other medical consumables. All the products have been sold in 34 provincial-level administrative regions in China, with 15 of them sold in more than 30 countries worldwide. The Company has received a number of quality-related manufacturing designations and has registered 17 products with the U.S. Food and Drug Administration allowing their products to enter the U.S. market. For more information, please visit the Company’s website: https://www.workmedtech.com/corporate.</p>
<div class="lb-trans"><p>WORK Medical Technology Group LTD 通過其子公司 Work（杭州）醫療器械有限公司及其在中國的子公司，是一家醫療器械供應商，開發和製造 I 類和 II 類醫療器械，並通過在中國的運營子公司銷售 I 類和 II 類一次性醫療器械。公司擁有多樣化的產品組合，包括 21 種產品，涵蓋定製和多功能口罩及其他醫療耗材。所有產品已在中國 34 個省級行政區域銷售，其中 15 種產品已在全球 30 多個國家銷售。公司獲得了多項與質量相關的製造認證，並已向美國食品藥品監督管理局註冊了 17 種產品，允許其產品進入美國市場。有關更多信息，請訪問公司網站：https://www.workmedtech.com/corporate。</p>
</div><p><strong><em>Forward-Looking Statements</em></strong></p>
<div class="lb-trans"><p><strong><em>前瞻性聲明</em></strong></p>
</div><p><em>This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Any forward-looking statements in this press release are based on the Company’s current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results set forth in the Company’s annual report on Form 20-F and other documents filed by the Company with the U.S. Securities and Exchange Commission. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.</em></p>
<div class="lb-trans"><p><em>本新聞稿包含前瞻性聲明，包括根據 1995 年《私人證券訴訟改革法》安全港條款作出的聲明。這些聲明可能通過諸如 “旨在”、“預期”、“相信”、“可能”、“估計”、“期望”、“預測”、“目標”、“打算”、“可能”、“計劃”、“可能的”、“潛在的”、“尋求”、“將會” 等詞語或類似表達來識別，旨在識別前瞻性聲明。本新聞稿中任何不是歷史事實的聲明可能被視為前瞻性聲明。本新聞稿中的任何前瞻性聲明僅基於公司截至本聲明日期的當前預期、估計和預測，並受到可能導致實際結果與這些前瞻性聲明中所列或暗示的結果顯著不同的多種風險和不確定性的影響。儘管公司相信這些前瞻性聲明中表達的預期是合理的，但無法保證這些預期會被證明是正確的，公司提醒投資者，實際結果可能與預期結果顯著不同，並鼓勵投資者審查可能影響其未來結果的其他因素，這些因素在公司提交給美國證券交易委員會的 20-F 表格年報和其他文件中列出。公司明確聲明，除法律要求外，沒有義務更新任何前瞻性聲明。</em></p>
</div><p><strong>For more information, please contact:</strong></p>
<div class="lb-trans"><p><strong>如需更多信息，請聯繫：</strong></p>
</div><p><strong>WORK Medical Technology Group LTD</strong></p>
<div class="lb-trans"><p><strong>WORK Medical Technology Group LTD</strong></p>
</div><p>Investor Relations Department</p>
<div class="lb-trans"><p>投資者關係部</p>
</div><p>Email: ir@workmedtech.com</p>
<div class="lb-trans"><p>電子郵件：ir@workmedtech.com</p>
</div><p><strong>Ascent Investor Relations LLC</strong></p>
<div class="lb-trans"><p><strong>Ascent Investor Relations LLC</strong></p>
</div><p>Tina Xiao</p>
<div class="lb-trans"><p>Tina Xiao</p>
</div><p>Phone: +1-646-932-7242</p>
<div class="lb-trans"><p>電話：+1-646-932-7242</p>
</div><p>Email: investors@ascent-ir.com</p>
<div class="lb-trans"><p>電子郵件：investors@ascent-ir.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qUTROeU0zTXpNME5EazRJelV3TURFeU56UXhNUT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxNjQ4NyM3MzM0NDk4IzUwMDEyNzQxMQ=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MzMwMTJhOTMtZjc1Zi00NTM1LTkyM2ItMWFhNDJjZWYwZGI5LTUwMDEyNzQxMS0yMDI1LTEyLTI0LWVu/tiny/WORK-Medical-Technology-Group-.png" alt="" original-src="https://ml.globenewswire.com/media/MzMwMTJhOTMtZjc1Zi00NTM1LTkyM2ItMWFhNDJjZWYwZGI5LTUwMDEyNzQxMS0yMDI1LTEyLTI0LWVu/tiny/WORK-Medical-Technology-Group-.png"/></p>

WORK Medical Technology Group LTD 宣佈將進行 1 股合併為 100 股的反向股票分割，該措施將於2025年12月29日生效 | WOK 股票新聞